



**ASX/Media Release**

**15 October 2020**

## **Receipt of R&D Tax Incentive Rebate**

**Melbourne, Australia; 15 October 2020** Acrux Limited (ASX:ACR, “**Acrux**” or the “**Company**”) is pleased to announce that the Company’s 100% owned investee company Acrux Pharma Pty Ltd has received its R&D Tax Incentive Rebate from the Australian Taxation Office of \$1,806,428 for the 2019/2020 financial year.

In addition, Acrux Commercial Pty Ltd anticipates receipt of its R&D Tax Incentive Rebate for the financial year 2019/2020 in the near future.

The R&D Tax Incentive is an Australian Government program under which companies receive cash refunds for 43.5% of eligible expenditure on research and development.

Authorised by the Board of Acrux Limited.

**For more information, please contact:**

### **General enquiries**

**Michael Kotsanis**

**Acrux Limited**

**CEO & Managing Director**

P: + 61 3 8379 0100

E: [michael.kotsanis@acrux.com.au](mailto:michael.kotsanis@acrux.com.au)

---

### **About Acrux**

Acrux (ASX: ACR) is a pharmaceutical company dedicated to developing and commercialising topical pharmaceuticals. Incorporated in 1998 and using in house facilities and capabilities, Acrux has successfully developed and commercialised through licensees a number of topically applied pharmaceutical products in the US and Europe. Acrux is developing of a range of generic products for the US market by leveraging its on-site laboratories, GMP manufacturing suite, clinical and commercial experience to bring affordable products to market. Acrux encourages collaboration and is well positioned to discuss partnering and product development.

For further information on Acrux, visit [www.acrux.com.au](http://www.acrux.com.au)